Fluoguide - precli data on FG001 effect in treatment cancer
-
Copenhagen, Denmark, 23 August 2021. FluoGuide A/S ("FluoGuide" or the "Company") is pleased to announce the first publication of preclinical data where the Company's compound FG001 is used as a photothermal therapy agent for treatment of cancer. The new feature of FG001 complements the surgical targeting and opens new opportunities for the realization of clinical and commercial potential of the Company's uPAR-targeting technology platform.
Link/Full details:
https://news.cision.com/fluoguide/r/publication-of-promising-preclinical-data-on-fg001s-effect-in-treatment-of-cancer,c3401276Publication:
https://www.oncotarget.com/article/28013/pdf/ -
(PDF) Q2 2021 Regnskab og highlights for Fluoguide:
https://fluoguide.com/wp-content/uploads/FluoGuide-Q2-2021-report-Final.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind